Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study);Seguridad y tolerabilidad en la fase inicial del tratamiento con interferón beta-1a 44 microgramos en pauta lenta frente a pauta rápida en pacientes con esclerosis múltiple (estudio PARALEN)

Revista de Neurologia

Volumn 48, Issue 10, 2009, Pages 505-508

  Hernández Pérez, Miguel Ángel ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

Demyelinating disease; Escalating dose; Immunomodulatory; Interferon beta 1a; Multiple sclerosis; Observational study; Treatment

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; SPAIN; TREATMENT OUTCOME;

EID: 65949098919     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4810.2008423     Document Type: Article

References (14)

1. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-1636
2. Gold R, Rieckmann P, Chang P, Abdalla J, PRISMS Study Group. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol 2005; 12: 649-656 (Pubitemid 41117291)
3. Cristiano E, Arcega R, Correale J, Gabbay AA, Lander-Delgado R, Macías-Islas MA, et al. Recomendaciones para la optimización del tratamiento de la esclerosis múltiple en Latinoamérica. Rev Neurol 2007; 44: 494-498
4. The Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon beta-1a dose response in relapsing-remitting MS. Neurology 1999; 53: 679-686
5. PRISMS Study Group. Randomised, double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504 (Pubitemid 28512925)
6. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS. The EVIDENCE trial. Neurology 2002; 59: 1496-1506
7. Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005; 239: 67-74.
8. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460
9. Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, et al. Enhanced benefit of increasing interferon-b 1a dose and frequency in relapsing MS: the EVIDENCE trial. Arch Neurol 2005; 62: 785-792
10. Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1489-1496
11. Álvarez-Cermeño JC. Lesión axonal inicial en la esclerosis múltiple. Razones para un tratamiento precoz. Rev Neurol 2002; 35: 221-227
12. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-178
13. Ficha técnica autorizada de Rebif, mayo de 2008. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Rebif/H-136-PI-es.pdf.
14. Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, et al, Rebif New Formulation Study Group. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif new formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler 2009; 15: 219-228